EDSA - Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
- On Sep 20, EDSA reports positive p2 data. On a request of the DSMB (Data and Safety Monitoring Board), p2 portion of EDSA's ongoing p2/3 trial was "preemptively unblinded".
- Using Cox's Proportional Hazard Model, EDSA reports that patients treated with EB05, their monoclonal antibody candidate, showed a 68.5% reduction in the risk of dying over the placebo at Day28.
- This positive news doubled EDSA's valuation, sending the stock from $5.88 on Sep 17 to a close of $11.92 on Sep 20, and then retreating to $8.32 on Sep 21.
- I take a look at the data and share my thoughts here.
For further details see:
Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients